Therapeutic Letter

Reducing prescribing cascades

Aaron M. Tejani, Thomas L. Perry
African Journal of Primary Health Care & Family Medicine | Vol 17, No 1 | a4929 | DOI: https://doi.org/10.4102/phcfm.v17i1.4929 | © 2025 Aaron M. Tejani, Thomas L. Perry | This work is licensed under CC Attribution 4.0
Submitted: 14 February 2025 | Published: 31 March 2025

About the author(s)

Aaron M. Tejani, Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada
Thomas L. Perry, Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, Canada

Abstract

Prescribing cascades contribute to the increasing prevalence of polypharmacy and its associated risks, where a drug-induced adverse event is misinterpreted as a new condition and treated with additional medications. Notable cascades include the use of anticholinergics leading to cognitive impairment, dyspepsia or constipation, which then prompt prescriptions for dementia medications, proton pump inhibitors or laxatives, respectively. Similarly, calcium channel blockers and gabapentinoids often induce oedema, resulting in unnecessary diuretic use. Strategies for prevention include careful review of adverse effects, deprescribing where appropriate and clinician education to improve symptom interpretation and prescribing practices. Recognising these cascades can mitigate unnecessary interventions and improve patient outcomes.


Keywords

prescribing cascade; polypharmacy; adverse drug events; deprescribing

Metrics

Total abstract views: 424
Total article views: 370


Crossref Citations

No related citations found.